
News|Articles|July 1, 2006
Oncology NEWS International
- Oncology NEWS International Vol 15 No 7
- Volume 15
- Issue 7
ChemGenex Launches Trial of Ceflatonin in TKI-Resistant CML
ChemGenex Launches Trial of Ceflatonin in TKI-Resistant CML
Advertisement
MENLO PARK, CalifChem-Genex Pharmaceuticals has launched a multinational phase II/III trial of Ceflatonin (homoharringtonine, HHT) in chronic myeloid leukemia patients who have the T315I bcr-abl point mutation, which makes them resistant to tyrosine kinase inhibitors (TKIs) such as imatinib (Gleevec). In April, FDA granted Ceflatonin orphan drug status for the treatment of CML.
Articles in this issue
over 19 years ago
High-Quality Screening Colonoscopy Priority for GI Docsover 19 years ago
Genentech Seeks Expanded Use of Avastin in Breast Cancerover 19 years ago
Denosumab Suppresses Bone Resorption in Breast Ca Metsover 19 years ago
FDA Approves Priority Review of Merck's Zolinza (Vorinostat)over 19 years ago
FDA Approves Revlimid for Myeloma Rxover 19 years ago
Real-Time RT Planning, Delivery in the Bronxover 19 years ago
Phase III Trial of Enzastaurin for NHL Patients Initiatedover 19 years ago
Racial Disparities in Prostate Ca RecurrenceNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
Modifiable Risk Factors Suggest Potential for Improving Cancer Prevention
2
Barriers to CAR T-Cell Referral and Center Access in Multiple Myeloma
3
2026 Tandem Meetings: What’s the Latest Research in Multiple Myeloma?
4
Exploring The Impact of ADTs on Cardiac Risk in Prostate Cancer Treatment
5




































